Gynecologic Oncology practice @MassGenNews. Researching how real-world cancer care affects real-world patients. He/his/him/himself
Joined March 2013
- Tweets951
- Following1.2K
- Followers1.2K
- Likes2K
Alex Melamed retweeted
Excited to share our randomized controlled trial published in @JCO_ASCO showing that facilitated cascade testing increased genetic testing among relatives of individuals with BRCA1/2. @RauhHainMD @karenluMD @headofmelon @UTMDAnderson @MelissaFrey2
🔗 ascopubs.org/doi/full/10.120…
What an honor to work with the amazing team that has turned @IJGConline into an academic powerhouse! @pedroramirezMD, thank you for your mentorship and for being our captain years. @RParejaGineOnco, so excited for your leadership going forward!
Thank you, Alex @headofmelon for your outstanding service as IJGC #AssociateEditor 💙
💡 bit.ly/432CurA
@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde
Alex Melamed retweeted
Thank you, Alex @headofmelon for your outstanding service as IJGC #AssociateEditor 💙
💡 bit.ly/432CurA
@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde
Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.
For patients with advanced-stage ovarian cancer, higher utilization of neoadjuvant chemotherapy at high-volume centers was associated with the lowest 90-day surgical mortality and longest 60-month survival. ja.ma/415zwCx
Alex Melamed retweeted
Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work.
Grateful to work with such an amazing team! @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD
🎙️ New #IJGCConversations Episode!
🚨 Radiation alone vs. Chemoradiation in Intermediate Risk #CervicalCancer with @nagustiga and @dviverosc
🎧 Tune in now and stay ahead in #GynOnc!
🔗 bit.ly/43Wmg5b
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @HelenaObermair @sofiabigardiGMD @marina_rosanu @ChakraRim @FilippoCapom @mcgouveia_ @MDAndersonnews
Alex Melamed retweeted
Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming patient care but raise important questions about the preparation of fellows in surgical training.
@headofmelon @dviverosc @RauhHainMD @NiteckiRoni
Gynecologic oncology is moving towards less invasive surgical methods and decreased surgery overall, which likely benefits patients but also raises challenges for surgical training and the equitable access. ja.ma/3DNOWmf
LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno
LANCE RCT: A minimally invasive surgery for advanced ovarian cancer after neoadjuvant chemotherapy is feasible and may reduce postoperative complications compared to laparotomy. ja.ma/4eBRbpz
Alex Melamed retweeted
#cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this important manuscript!
authors.elsevier.com/c/1k7m2…
@RauhHainMD @headofmelon @markaclapp @abigailflynt @dviverosc @nagustiga @MDAndersonNews @AJOG_thegray
Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and @AlexBercowMD getting these pictures into the literature.
pubs.rsna.org/doi/10.1148/ry…
NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.
Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. ja.ma/4dNCjEa
Alex Melamed retweeted
Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. ja.ma/4dNCjEa
Thanks @IJGConline and @pedroramirezMD for this great honor.
📣 Great news!!!
Dr. Alexander Melamed joins the #IJGC #AssociateEditors team 🔥 🔥
Welcome Alex!🤩
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4
A new paper by super intern Katy Abel looks at the use and efficacy of primary site surgery in metastatic cancer. There is a lot of heterogeneity across cancer sites, raising essential questions about how, and if, we know when surgery is helpful
onlinelibrary.wiley.com/doi/…
A new paper by Jason Silberman @JSilby3: who is on the market for the gyn onc fellowship spot!
tinyurl.com/2pzjm748
cytotoxic NACT has increased for stage III&IV low-grade serous ovarian cancer in last 15y w/o evidence that this approach is effective in this cancer type
Nice study from Vrede et al:
The molecular subtype may not be prognostically important for low-grade endometrioid endometrial cancer
Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer ja.ma/3jNizKm via @JAMANetworkOpen part of @JAMANetwork
Alex Melamed retweeted
Our latest study in @JAMASurgery revealed that spending for cancer surgery decreased significantly among Medicare beneficiaries. Read the full text: jamanetwork.com/journals/jam… @headofmelon @NancyKeatingMD @anaeze_offodile
